Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study - PubMed (original) (raw)
Clinical Trial
Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study
A Rossi et al. Acta Psychiatr Scand. 1997 Jan.
Abstract
The aim of this study was to evaluate the effects of a new antipsychotic compound on negative symptoms and cognitive deficit in schizophrenia. Psychiatric symptoms and cognition were assessed in 25 patients with schizophrenia, at baseline and after they had taken risperidone for 4 weeks. The Positive and Negative Symptoms Scale (PANSS), the Wisconsin Card Sorting Test (WCST) and two WAIS sub-tests were used to assess the patients. After the study period, both negative and positive symptoms and also measures of cognitive performance improved significantly. The WCST results correlated with negative symptom scores before and after treatment. This suggests that negative symptoms and cognitive deficit have a common underlying substrate which is the target of the risperidone treatment. Our data show that risperidone may have a substantial effect on complex cognitive functions in schizophrenia, and they suggest that certain cognitive deficits are relatively dependent on the negative symptoms of this disorder.
Similar articles
- The effect of risperidone on cognition in patients with schizophrenia.
Stip E, Lussier I. Stip E, et al. Can J Psychiatry. 1996 Oct;41(8 Suppl 2):S35-40. doi: 10.1177/070674379604100802. Can J Psychiatry. 1996. PMID: 8899249 - Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests.
Borkowska A, Araszkiewicz A, Rajewski A, Rybakowski JK. Borkowska A, et al. Neuropsychobiology. 2002;46(2):85-9. doi: 10.1159/000065417. Neuropsychobiology. 2002. PMID: 12378125 - Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ. Riedel M, et al. Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. doi: 10.1007/s00406-007-0739-x. Epub 2007 Jul 14. Eur Arch Psychiatry Clin Neurosci. 2007. PMID: 17629731 Clinical Trial. - Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Saavedra-Velez C, et al. J Clin Psychiatry. 2009 Jan;70(1):104-12. doi: 10.4088/jcp.07r03982. Epub 2008 Nov 18. J Clin Psychiatry. 2009. PMID: 19026265 Review. - Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
[No authors listed] [No authors listed] J Clin Psychiatry. 1998;59 Suppl 12:35-40. J Clin Psychiatry. 1998. PMID: 9766618 Review.
Cited by
- Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.
Purdon SE. Purdon SE. J Psychiatry Neurosci. 2000 Mar;25(2):108-16. J Psychiatry Neurosci. 2000. PMID: 10740984 Free PMC article. Review. No abstract available. - Clinical potential of omega-3 fatty acids in the treatment of schizophrenia.
Emsley R, Oosthuizen P, van Rensburg SJ. Emsley R, et al. CNS Drugs. 2003;17(15):1081-91. doi: 10.2165/00023210-200317150-00003. CNS Drugs. 2003. PMID: 14661986 Review. - The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine.
Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, Ali M, Marcus R. Kern RS, et al. Psychopharmacology (Berl). 2006 Aug;187(3):312-20. doi: 10.1007/s00213-006-0428-x. Epub 2006 Jun 30. Psychopharmacology (Berl). 2006. PMID: 16810506 Clinical Trial. - Improved antisaccade performance with risperidone in schizophrenia.
Burke JG, Reveley MA. Burke JG, et al. J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):449-54. doi: 10.1136/jnnp.72.4.449. J Neurol Neurosurg Psychiatry. 2002. PMID: 11909901 Free PMC article. Clinical Trial. - Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.
Harvey PD, Green MF, McGurk SR, Meltzer HY. Harvey PD, et al. Psychopharmacology (Berl). 2003 Sep;169(3-4):404-11. doi: 10.1007/s00213-002-1342-5. Epub 2003 Feb 18. Psychopharmacology (Berl). 2003. PMID: 12590356 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical